Cyclooxygenase-2 inhibition: Vascular inflammation and cardiovascular risk

被引：14

作者：

Cipollone F. ^{[1
]}

Fazia M.L. ^{[1
]}

机构：

[1] Centro Regionale per la Prevenzione dell'Aterosclerosi, 66013 Chieti, Via Colle dell'Ara

来源：

Current Atherosclerosis Reports | 2006年 / 8卷 / 3期

关键词：

Celecoxib; Naproxen; Atherosclerotic Plaque; Rofecoxib; Etoricoxib;

D O I：

10.1007/s11883-006-0080-2

中图分类号：

学科分类号：

摘要：

The inducible isoform of cyclooxygenase-2 (COX-2) plays a role in pathophysiologic processes like inflammation and pain but is also constitutively expressed in tissues such as the kidney or vascular endothelium, where it exerts important physiologic functions. Although much evidence exists that implicates COX-2 in atherosclerosis, its role in this setting remains substantially uncertain. This observation is also confirmed by the results of clinical trials of selective COX-2 inhibitors. Treatment with these drugs, developed with the assumption that they would be as effective as nonselective COX inhibitors but without their gastrointestinal side effects, has been reported to be associated with an increased cardiovascular risk. In this article, we review the pattern of expression of COX-2 in the cellular players of atherothrombosis, its role as a determinant of plaque vulnerability, and the vascular effects on prostanoid inhibition by COX-2 inhibitors. Copyright © 2006 by Current Science Inc.

引用

页码：245 / 251

页数：6

共 50 条

[1]

Ross R., Atherosclerosis - An inflammatory disease, N Engl J Med, 340, pp. 115-126, (1999)

[2]

Cipollone F., Prontera C., Pini B., Et al., Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability, Circulation, 104, pp. 921-927, (2001)

[3]

Cipollone F., Fazia M., Iezzi A., Et al., Balance between PGD synthase and PGE synthase is a major determinant of atherosclerotic plaque instability in humans, Arterioscler Thromb Vasc Biol, 24, pp. 1259-1265, (2004)

[4]

Baigent C., Patrono C., Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: A reappraisal, Arthritis Rheum, 48, pp. 12-20, (2003)

[5]

Dubois R.N., Abramson S.B., Crofford L., Et al., Cyclooxygenase in biology and disease, FASEB J, 12, pp. 1063-1073, (1998)

[6]

Smith W.L., Langenbach R., Why there are two cyclooxygenase isozymes, J Clin Invest, 107, pp. 1491-1495, (2001)

[7]

Patrono C., Prevention of myocardial infarction and stroke by aspirin: Different mechanisms? Different dosage?, Thromb Res, 92, (1998)

[8]

Xie W., Chipman J.G., Roberson D.L., Et al., Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing, Proc Natl Acad Sci U S A, 88, pp. 2682-2686, (1991)

[9]

Cipollone F., Fazia M., Mezzetti A., Novel determinants of plaque instability, J Thromb Haemost, 3, pp. 1962-1975, (2005)

[10]

Hong B.K., Kwon H.M., Lee B.K., Et al., Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions, Yonsei Med J, 41, pp. 82-88, (2000)

← 1 2 3 4 5 →